Feel Comfortable Holding PCSK9 Inhibitors During a Hospital Stay
May 2017
You'll hear buzz about using the PCSK9 inhibitors, evolocumab (Repatha) or alirocumab (Praluent), in patients with CV disease.
These injectable meds lower LDL cholesterol by about 60%...even in those on a high-intensity statin (atorvastatin 80 mg, etc).
Now evidence suggests that adding evolocumab to a statin in patients with CV disease and other risks (diabetes, etc) prevents one more CV event for every 74 patients treated for about 2 years.
Get concise advice on drug therapy, plus unlimited access to CE
Hospital Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote